Postnatal rosiglitazone administration to neonatal rat pups does not alter the young adult metabolic phenotype
Related Experiment Video
Updated: May 27, 2026
Monitoring Blood Glucose in Mouse Offspring After Intracytoplasmic Sperm Injection
Published on: May 17, 2024
Nghia C Truong1, Afshan Abbasi, Reiko Sakurai
1Department of Pediatrics, David Geffen School of Medicine, University of California at Los Angeles, Torrance, Calif., USA.
Insights
Neonatal exposure to rosiglitazone (RGZ), a PPARγ agonist, does not affect adult metabolic health. This study confirms the safety of RGZ for lung development without long-term metabolic consequences.
Area of Science:
- Endocrinology
- Metabolic Research
- Neonatal Development
Background:
- Rosiglitazone (RGZ), a PPARγ agonist, aids neonatal lung maturation.
- Potential long-term effects of neonatal RGZ on adult metabolism remain uninvestigated.
Purpose of the Study:
- To assess the impact of early postnatal RGZ administration on young adult metabolic phenotype.
- To determine if neonatal RGZ exposure influences later metabolic programming.
Main Methods:
- Neonatal rats received daily saline or RGZ for 7 days.
- Young adult rats (11-14 weeks) underwent glucose and insulin tolerance tests.
- Deuterium labeling and analysis of blood and tissue metabolic parameters were performed.
Main Results:
- No significant differences observed in adult body weight, glucose/insulin tolerance, or plasma lipid profiles.
- Neonatal RGZ did not affect insulin, glucagon, cardiac troponin, or fatty acid synthesis.
- Tissue adipogenic differentiation remained unaltered by early postnatal RGZ exposure.
Conclusions:
- Early neonatal treatment with RGZ does not alter adult metabolic programming.
- Neonatal RGZ administration does not lead to an altered metabolic phenotype in young adulthood.
- These findings support the safety of PPARγ agonists as a lung-protective strategy.
Background:
Rosiglitazone (RGZ), a peroxisome proliferator-activated receptor-γ (PPARγ) agonist, significantly enhances lung maturation without affecting blood biochemical and metabolic profiles in the newborn period. However, whether this exposure to RGZ in neonatal life alters the adult metabolic phenotype is not known.
Objective:
To determine the effects of early postnatal administration of RGZ on the young adult metabolic phenotype.
Methods:
Newborn rat pups were administered either saline or RGZ for the first 7 days of life. At 11-14 weeks, glucose and insulin tolerance tests and deuterium labeling were performed. Blood and tissues were analyzed for various metabolic parameters.
Results:
Overall, there was no effect of early postnatal RGZ administration on young adult body weight, glucose and insulin tolerance, plasma cholesterol and triglyceride profiles, insulin, glucagon, cardiac troponin, fatty acid synthesis, or tissue adipogenic differentiation.
Conclusions:
Treatment with RGZ in early neonatal life does not alter later developmental metabolic programming or lead to an altered metabolic phenotype in the young adult, further re-enforcing the safety of PPARγ agonists as a novel lung-protective strategy.
